Quantitative analysis of endobronchial ultrasound elastography in computed tomography-negative mediastinal and hilar lymph nodes.
Bronchoscopy
elastography
endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
lung cancer
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
25
05
2020
revised:
30
06
2020
accepted:
30
06
2020
pubmed:
22
7
2020
medline:
20
11
2021
entrez:
22
7
2020
Statut:
ppublish
Résumé
Endobronchial ultrasound (EBUS) elastography assists in the differentiation of benign and malignant lymph nodes (LNs) during transbronchial needle aspiration (TBNA). However, previous studies have not compared B-mode sonographic images (BSIs) and EBUS elastography images (EEIs) with final pathological diagnoses in radiologically normal-sized (computed tomography [CT]-negative) LNs. Consecutive patients with CT-negative LNs, who received EBUS-TBNA, were retrospectively reviewed. Images of BSIs and EEIs of each LN were stored and independently evaluated. EEIs were assessed by calculating the stiffness area ratio (SAR, blue/overall areas). The receiver operating characteristic curve was used to calculate the cutoff value for the SAR. Diagnostic test parameters were evaluated for each EBUS finding. A total of 132 patients (149 LNs) were enrolled, and the median SAR of malignant LNs was significantly higher than that of benign LNs (0.58 vs. 0.32, P < 0.001). At the SAR cutoff of 0.41, the sensitivity, specificity, positive predictive value, negative predictive value (NPV), and diagnostic accuracy rate (DAR) of elastography were 88.2%, 80.2%, 78.9%, 89.0%, and 83.9%, respectively. The logistic regression analysis showed that elastography was the strongest predictor of malignancy (odds ratio, 18.5; 95% confidence interval [CI]: 6.48-52.6; P < 0.001). The highest NPV (96.6%) was achieved with a combination of BSIs and EEIs. EBUS elastography predicted malignant LNs with a high DAR and NPV in CT-negative LNs. The NPV was highest when EEIs were combined with BSIs. Therefore, the combined evaluation of CT-negative LNs using EEIs and BSIs may help bronchoscopists perform EBUS-TBNA more efficiently. SIGNIFICANT FINDINGS OF THE STUDY: Endobronchial ultrasound elastography accurately predicted malignancy with a high diagnostic accuracy rate and negative predictive value in radiologically normal-sized lymph nodes. The additional use of B-mode sonographic features resulted in a higher negative predictive value. Endobronchial ultrasound elastography can guide the accurate collection of specimens with transbronchial needle aspiration, even in radiologically normal-sized lymph nodes. It can also readily distinguish benign and malignant lymph nodes, thus avoiding unnecessary punctures.
Sections du résumé
BACKGROUND
Endobronchial ultrasound (EBUS) elastography assists in the differentiation of benign and malignant lymph nodes (LNs) during transbronchial needle aspiration (TBNA). However, previous studies have not compared B-mode sonographic images (BSIs) and EBUS elastography images (EEIs) with final pathological diagnoses in radiologically normal-sized (computed tomography [CT]-negative) LNs.
METHODS
Consecutive patients with CT-negative LNs, who received EBUS-TBNA, were retrospectively reviewed. Images of BSIs and EEIs of each LN were stored and independently evaluated. EEIs were assessed by calculating the stiffness area ratio (SAR, blue/overall areas). The receiver operating characteristic curve was used to calculate the cutoff value for the SAR. Diagnostic test parameters were evaluated for each EBUS finding.
RESULTS
A total of 132 patients (149 LNs) were enrolled, and the median SAR of malignant LNs was significantly higher than that of benign LNs (0.58 vs. 0.32, P < 0.001). At the SAR cutoff of 0.41, the sensitivity, specificity, positive predictive value, negative predictive value (NPV), and diagnostic accuracy rate (DAR) of elastography were 88.2%, 80.2%, 78.9%, 89.0%, and 83.9%, respectively. The logistic regression analysis showed that elastography was the strongest predictor of malignancy (odds ratio, 18.5; 95% confidence interval [CI]: 6.48-52.6; P < 0.001). The highest NPV (96.6%) was achieved with a combination of BSIs and EEIs.
CONCLUSIONS
EBUS elastography predicted malignant LNs with a high DAR and NPV in CT-negative LNs. The NPV was highest when EEIs were combined with BSIs. Therefore, the combined evaluation of CT-negative LNs using EEIs and BSIs may help bronchoscopists perform EBUS-TBNA more efficiently.
KEY POINTS
SIGNIFICANT FINDINGS OF THE STUDY: Endobronchial ultrasound elastography accurately predicted malignancy with a high diagnostic accuracy rate and negative predictive value in radiologically normal-sized lymph nodes. The additional use of B-mode sonographic features resulted in a higher negative predictive value.
WHAT THIS STUDY ADDS
Endobronchial ultrasound elastography can guide the accurate collection of specimens with transbronchial needle aspiration, even in radiologically normal-sized lymph nodes. It can also readily distinguish benign and malignant lymph nodes, thus avoiding unnecessary punctures.
Identifiants
pubmed: 32691537
doi: 10.1111/1759-7714.13579
pmc: PMC7471032
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2590-2599Subventions
Organisme : JSPS
ID : JP19K16966
Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
J Ultrasound Med. 2015 Sep;34(9):1645-50
pubmed: 26269299
Radiology. 2005 Aug;236(2):458-64
pubmed: 16040902
World J Gastrointest Oncol. 2014 Sep 15;6(9):360-8
pubmed: 25232461
Chest. 2010 Sep;138(3):641-7
pubmed: 20382710
J Thorac Cardiovasc Surg. 2019 Oct;158(4):1220-1229.e2
pubmed: 31147169
Ann Thorac Surg. 2018 Oct;106(4):1251-1257
pubmed: 29738756
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Eur J Cancer. 2009 May;45(8):1389-96
pubmed: 19124238
Radiology. 2005 Oct;237(1):202-11
pubmed: 16118150
JAMA. 2013 Jun 19;309(23):2457-64
pubmed: 23780458
Chest. 2016 Mar;149(3):816-35
pubmed: 26402427
Ann Thorac Surg. 2014 Nov;98(5):1762-7
pubmed: 25149044
Radiol Oncol. 2015 Nov 27;49(4):334-40
pubmed: 26834519
N Engl J Med. 2017 Aug 31;377(9):849-861
pubmed: 28854088
Respiration. 2017;93(5):327-338
pubmed: 28324873
Lung Cancer. 2020 Jan;139:151-156
pubmed: 31805443
Endoscopy. 2015 Jun;47(6):545-59
pubmed: 26030890
Sci Rep. 2018 Feb 23;8(1):3571
pubmed: 29476168
Thorac Cancer. 2019 Oct;10(10):2000-2005
pubmed: 31474004
Clin Radiol. 2019 Oct;74(10):818.e17-818.e23
pubmed: 31420186
Br J Radiol. 2019 May;92(1097):20180341
pubmed: 30817169
Chest. 2013 May;143(5 Suppl):e211S-e250S
pubmed: 23649440
Respirology. 2017 Jul;22(5):972-977
pubmed: 28102963
J Bronchology Interv Pulmonol. 2019 Jul;26(3):155-165
pubmed: 30119069
Ann Am Thorac Soc. 2018 Jul;15(7):864-874
pubmed: 29684288
World J Gastroenterol. 2015 Dec 21;21(47):13212-24
pubmed: 26715804
Gastroenterology. 2005 Feb;128(2):343-50
pubmed: 15685546
J Thorac Oncol. 2012 Jun;7(6):1009-14
pubmed: 22525556
Respiration. 2015;90(6):499-506
pubmed: 26571232
J Formos Med Assoc. 2019 Jan;118(1 Pt 3):436-443
pubmed: 30007831
Thorax. 2009 Sep;64(9):757-62
pubmed: 19454408
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Lung Cancer. 2020 Apr;142:9-12
pubmed: 32062200
Jpn J Clin Oncol. 2014 Oct;44(10):956-62
pubmed: 25121724
Clin Respir J. 2020 May;14(5):488-494
pubmed: 32034995
J Cancer. 2017 Jul 2;8(10):1843-1848
pubmed: 28819382